This may explain the lack of clinical efficacy with anti-IL-17 [16] and IL-17 receptor [15] approaches in severe asthma and that perhaps a broader approach is required to block additional Th17-associated cytokines such IL-22 and IL-26. Here, IL26 is linked to asthma.